Combination Study of SV-BR-1-GM With Retifanlimab

NCT03328026 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer
Breast Neoplasm
Metastatic Breast Cancer
Breast Cancer Metastatic

Interventions

BIOLOGICAL: SV-BR-1-GM
DRUG: Low dose cyclophosphamide
DRUG: Interferon Inoculation
DRUG: retifanlimab

Sponsor

BriaCell Therapeutics Corporation

Collaborators

[object Object]